drugset
drugset / Trial / NCT05277285

STS Administration on Coronavirus Disease (COVID-19) Patients in Critical Care

NCT05277285 ↗

Phase 2 Unknown 30 enrolled Hellenic Institute for the Study of Sepsis
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose is to describe the safety of administration of three doses of STS to critically ill patients with confirmed COVID-19. A secondary purpose is to describe data on the clinical efficacy of administration of up to three doses of STS in critically ill patients with confirmed COVID-19.

Timeline

Start
2022-04-01
Primary completion
2023-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Thiosulfate Diagnostic / imaging agent 12.5 g Intravenous

Indications

COVID-19